Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
iSpecimen Inc. (ISPC)
USD2.16
-0.23 (-9.62%)
US NASDAQ Healthcare Medical - Diagnostics & Research
Address
450 Bedford Street 2420
Woburn, MA, US
Woburn, MA, US
CEO
Katharyn Field
Website
ispecimen.com
IPO
2021-06-17
CIK 1558569 ISIN US45032V3069
Description
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.16
-0.23 (-9.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
858.7K
Beta
1.62
Float Shares
137.5K
Free Float %
99.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.82% | -7.33% | -39.58% | -68.40% | -81.19% | -69.62% | -93.52% | -99.67% | -99.94% | -99.94% | -99.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
2.16
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-23.78
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-79.2% Q1'26: -85.2% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+87.0% ★ Q1'26: -185.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-344.0% Q1'26: -2,154.9% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-543.2% Q1'26: -1,627.1% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%— Q1'26: +580.2% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+547.5% Q1'26: -80.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.03× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
|---|---|---|---|---|---|---|
| Revenue |
11.14M
est: 12.10M (-8.0%)
|
10.40M
est: 10.12M (+2.8%)
|
9.93M
est: 10.51M (-5.5%)
|
9.29M
est: 11.08M (-16.1%)
|
1.93M
est: 12.38M (-84.4%)
|
37.85M
37.85M – 37.85M
+205.7% YoY
|
| EBITDA |
-5.86M
est: -8.40M (+30.3%)
|
-8.80M
est: -7.02M (-25.4%)
|
-8.80M
est: -8.95M (+1.6%)
|
-12.73M
est: -9.44M (-34.9%)
|
-8.75M
est: -10.55M (+17.1%)
|
-32.23M
-32.23M – -32.23M
-205.7% YoY
|
| EBIT |
-6.86M
est: -9.41M (+27.1%)
|
-10.01M
est: -7.87M (-27.2%)
|
-10.87M
est: -9.62M (-13.0%)
|
-12.67M
est: -10.14M (-24.9%)
|
-10.48M
est: -11.34M (+7.6%)
|
-34.65M
-34.65M – -34.65M
-205.7% YoY
|
| Net Income |
-8.96M
est: -28.86M (+68.9%)
|
-10.25M
est: -18.41M (+44.3%)
|
-11.10M
est: -121.5K (-9,034.3%)
|
-12.50M
est: -81.00M (+84.6%)
|
-10.49M
est: -72.72M (+85.6%)
|
—
— – —
+100.0% YoY
|
| SGA |
9.40M
est: 12.55M (-25.1%)
|
12.37M
est: 10.49M (+17.9%)
|
11.68M
est: 15.89M (-26.5%)
|
12.65M
est: 16.75M (-24.5%)
|
5.77M
est: 18.72M (-69.2%)
|
57.23M
57.23M – 57.23M
+205.7% YoY
|
| EPS |
-980.40
est: -40.60 (-2,314.8%)
|
-818.80
est: -25.90 (-3,061.4%)
|
-49.20
est: -1.06 (-4,558.7%)
|
-703.20
est: -704.00 (+0.1%)
|
-91.20
est: -632.00 (+85.6%)
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.72M
OE per share TTM
-1,019.99
Owner's Yield
-62,315.35%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
2.00
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Andrew L. Ross | 1.33M | 15.23% | 1.33M | — | 1.33M | — | IN | United States | 2022-02-07 | ↗ |
| 2 | George H. Scholl | 843.2K | 9.70% | 843.2K | — | 843.2K | — | IN | United States | 2022-02-14 | ↗ |
| 3 | OBF Investments, LLC | 842.0K | 9.60% | 842.0K | — | 842.0K | — | OO | United States | 2022-02-14 | ↗ |
| 4 | JAMES G. WOLF | 544.3K | 6.13% | 503.3K | 41.0K | 503.3K | 41.0K | IN | U.S.A. | 2022-09-28 | ↗ |
| 5 | Empery Asset Management, LP | 437.5K | 5.34% | — | 437.5K | — | — | PN | Delaware | 2022-01-24 | ↗ |
| 6 | Martin D. Hoe | 437.5K | 5.34% | — | 437.5K | — | — | IN | Delaware | 2022-01-24 | ↗ |
| 7 | Ryan M. Lane | 437.5K | 5.34% | — | 437.5K | — | — | IN | Delaware | 2022-01-24 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GILL CAPITAL PARTNERS, LLC | 15.00 +15.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.13 +23.1% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 93.70 | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
336.00
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+336
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-07 | Lee Arphing | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-13 | Liang Yuying | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-09 | LIM ROBERT BRADLEY | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-25 | Paolone Richard | Director | A-Award | A | Option | 168 | 5.12 | 860.16 | 168 | D | ↗ |
| 2024-09-25 | Field Katharyn | Director | A-Award | A | Option | 168 | 5.12 | 860.16 | 168 | D | ↗ |
| 2024-09-25 | Dhaliwal Avtar | Director | A-Award | A | Option | 168 | 5.12 | 860.16 | 168 | D | ↗ |
| 2024-03-21 | Graham Elizabeth Ames | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-02 | Ross Andrew L. | Director | A-Award | A | Option | 10,000 | 0.53 | 5.3K | 33,525 | — | ↗ |
| 2024-01-02 | Mock Theresa L | Director | A-Award | A | Option | 10,000 | 0.53 | 5.3K | 16,672 | — | ↗ |
| 2024-01-02 | Gullans Steven R. Ph.D. | Director | A-Award | A | Option | 10,000 | 0.53 | 5.3K | 33,525 | — | ↗ |
| 2024-01-02 | Brooks John L. III | Director | A-Award | A | Option | 10,000 | 0.53 | 5.3K | 33,525 | — | ↗ |
| 2023-12-31 | Mock Theresa L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-14 | Bielak Benjamin | Officer | P-Purchase | A | Common Stock | 18,000 | 0.72 | 13.0K | 84,348 | — | ↗ |
| 2023-05-31 | Curley Tracy | Director / Officer | P-Purchase | A | Common Stock | 4,400 | 1.25 | 5.5K | 49,541 | — | ↗ |
| 2023-01-17 | Mullan Jill | Director | M-Exempt | D | Option | 66,637 | 0.00 | — | 10,000 | — | ↗ |
| 2023-01-06 | Ianelli Christopher | Director | M-Exempt | D | Option | 845 | 0.00 | — | 10,000 | — | ↗ |
| 2023-01-03 | Scholl George H. | Director | A-Award | A | Option | 10,000 | 1.41 | 14.1K | 23,525 | — | ↗ |
| 2023-01-03 | Ross Andrew L. | Director | A-Award | A | Option | 10,000 | 1.41 | 14.1K | 23,525 | — | ↗ |
| 2023-01-03 | Mullan Jill | Director | A-Award | A | Option | 10,000 | 1.41 | 14.1K | 76,637 | — | ↗ |
| 2023-01-03 | Ianelli Christopher | Director | A-Award | A | Option | 10,000 | 1.41 | 14.1K | 10,845 | — | ↗ |
| 2023-01-03 | Gullans Steven R. Ph.D. | Director | A-Award | A | Option | 10,000 | 1.41 | 14.1K | 23,525 | — | ↗ |
| 2023-01-03 | Brooks John L | Director | A-Award | A | Option | 10,000 | 1.41 | 14.1K | 23,525 | — | ↗ |
| 2023-01-03 | Basile Joseph J. | Director | A-Award | A | Option | 10,000 | 1.41 | 14.1K | 11,668 | — | ↗ |
| 2023-01-01 | Ross Andrew L. | Director | A-Award | A | Common Stock | 125 | 0.00 | — | 1,326,340 | — | ↗ |
| 2023-01-01 | Mullan Jill | Director | A-Award | A | Common Stock | 92 | 0.00 | — | 246,318 | — | ↗ |
| 2023-01-01 | Ianelli Christopher | Director | A-Award | A | Common Stock | 92 | 0.00 | — | 425,451 | — | ↗ |
| 2023-01-01 | Gullans Steven R. Ph.D. | Director | A-Award | A | Common Stock | 125 | 0.00 | — | 3,250 | — | ↗ |
| 2023-01-01 | Brooks John L. III | Director | A-Award | A | Common Stock | 125 | 0.00 | — | 3,250 | — | ↗ |
| 2023-01-01 | Basile Joseph J. | Director | A-Award | A | Common Stock | 63 | 0.00 | — | 63 | — | ↗ |
| 2022-12-31 | Scholl George H. | Director | — | I | Common Stock | 0 | 0.00 | — | 841,981 | — | ↗ |
| 2022-12-31 | Ross Andrew L. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Lawrence Margaret H. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Gullans Steven R. Ph.D. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Brooks John L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-28 | Basile Joseph J. | Director | — | D | Option | 1,668 | 1.50 | 2.5K | — | — | ↗ |
| 2022-11-01 | Curley Tracy | Officer | A-Award | A | Option | 100,000 | 1.61 | 161.0K | 100,000 | — | ↗ |
| 2022-11-01 | Bielak Benjamin | Officer | A-Award | A | Option | 30,000 | 1.61 | 48.3K | 57,952 | — | ↗ |
| 2022-10-24 | Mullan Jill | Director | J-Other | D | Common Stock | 18,229 | 0.00 | — | 179,589 | — | ↗ |
| 2022-10-24 | Ianelli Christopher | Director | J-Other | D | Option | 564 | 0.00 | — | 845 | — | ↗ |
| 2022-06-22 | Mullan Jill | Officer | F-InKind | D | Common Stock | 3,124 | 2.36 | 7.4K | 197,818 | — | ↗ |
| 2022-06-22 | Ianelli Christopher | Officer | F-InKind | D | Common Stock | 3,903 | 2.36 | 9.2K | 442,743 | — | ↗ |
| 2022-06-22 | Curley Tracy | Officer | F-InKind | D | Common Stock | 2,738 | 2.36 | 6.5K | 45,141 | — | ↗ |
| 2022-06-22 | Bielak Benjamin | Officer | F-InKind | D | Common Stock | 3,148 | 2.36 | 7.4K | 66,348 | — | ↗ |
| 2022-02-23 | Ianelli Christopher | Director / Officer | M-Exempt | A | Common Stock | 48,106 | 1.00 | 48.1K | 446,646 | — | ↗ |
| 2022-02-22 | Mullan Jill | Director / Officer | M-Exempt | D | Option | 3,099 | 1.00 | 3.1K | 67,201 | — | ↗ |
| 2022-02-22 | Ianelli Christopher | Director / Officer | M-Exempt | A | Common Stock | 3,099 | 1.00 | 3.1K | 398,540 | — | ↗ |
| 2021-12-31 | Mullan Jill | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | Ianelli Christopher | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | Curley Tracy | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | Bielak Benjamin | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-17 | Curley Tracy | Officer | P-Purchase | A | Common Stock | 2,000 | 5.12 | 10.2K | 10,000 | — | ↗ |
| 2021-11-16 | Ross Andrew L. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 5.19 | 5.2K | 1,314,524 | — | ↗ |
| 2021-11-16 | Curley Tracy | Officer | P-Purchase | A | Common Stock | 8,000 | 5.23 | 41.8K | 8,000 | — | ↗ |
| 2021-11-15 | Ross Andrew L. | Director / 10% Owner | P-Purchase | A | Common Stock | 500 | 5.30 | 2.7K | 1,313,524 | — | ↗ |
| 2021-11-10 | Ross Andrew L. | Director / 10% Owner | P-Purchase | A | Common Stock | 500 | 5.85 | 2.9K | 1,312,524 | — | ↗ |
| 2021-11-08 | Ross Andrew L. | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 5.73 | 5.7K | 1,312,024 | — | ↗ |
| 2021-07-30 | Scholl George H. | Director | A-Award | A | Non-Qualified Stock Options | 13,525 | 8.00 | 108.2K | 13,525 | — | ↗ |
| 2021-07-30 | Ross Andrew L. | Director / 10% Owner | A-Award | A | Non-Qualified Stock Options | 13,525 | 0.00 | — | 13,525 | — | ↗ |
| 2021-07-30 | Lawrence Margaret H. | Director | A-Award | A | Non-Qualified Stock Options | 13,525 | 8.00 | 108.2K | 13,525 | — | ↗ |
| 2021-07-30 | Gullans Steven R. Ph.D. | Director | A-Award | A | Non-Qualified Stock Options | 13,525 | 8.00 | 108.2K | 13,525 | — | ↗ |
| 2021-07-30 | Brooks John L | Director | A-Award | A | Non-Qualified Stock Options | 13,525 | 8.00 | 108.2K | 13,525 | — | ↗ |
| 2021-06-23 | Ross Andrew L. | Director / 10% Owner | P-Purchase | A | Common Stock | 400 | 6.52 | 2.6K | 1,311,024 | — | ↗ |
| 2021-06-21 | Ross Andrew L. | Director / 10% Owner | C-Conversion | D | Series A Preferred Stock | 355,005 | 0.00 | — | 0 | — | ↗ |
| 2021-06-21 | OBF Investments, LLC | 10% Owner | C-Conversion | A | Common Stock | 472,490 | 2,645,945.00 | 1.25T | 722,946 | — | ↗ |
| 2021-06-21 | Mullan Jill | Director / Officer | C-Conversion | A | Common Stock | 6,250 | 0.00 | — | 49,566 | — | ↗ |
| 2021-06-21 | Ianelli Christopher | Director / Officer | C-Conversion | A | Common Stock | 2,663 | 0.00 | — | 343,357 | — | ↗ |
| 2021-06-17 | Ross Andrew L. | Director / 10% Owner | P-Purchase | A | Common Stock | 100 | 6.27 | 627.00 | 1,310,624 | — | ↗ |
| 2021-06-16 | Ross Andrew L. | Director / 10% Owner | — | D | Series A Preferred Stock | 355,005 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | OBF Investments, LLC | 10% Owner | — | D | Series B Preferred Stock | 250,456 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | Mullan Jill | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 43,316 | — | ↗ |
| 2021-06-16 | Lawrence Margaret H. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | Ianelli Christopher | Director / Officer | — | D | Series A Preferred Stock | 2,663 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | Gullans Steven R. Ph.D. | Director | — | D | Option | 13,525 | 3.83 | 51.8K | 0 | — | ↗ |
| 2021-06-16 | Curley Tracy | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | Brooks John L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | Bielak Benjamin | Officer | — | D | Option | 4,508 | 1.00 | 4.5K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-4.4K
Shares Outstanding
138.9K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Benjamin Bielak Former Chief Information Officer | 192.0K | 215.0K | — | — | — | — | 406.6K | 0.00% | ↗ |
| 2 | 2024 | Tracy Curley Former Chief Executive Officer, Chief Financial Officer, Treasurer and Director | 329.3K | — | — | — | — | — | 329.3K | 0.00% | ↗ |
| 3 | 2023 | Tracy Curley Chief Executive Officer, Chief Financial Officer, Treasurer and Director | 350.0K | 87.5K | — | — | — | — | 437.5K | 0.00% | ↗ |
| 4 | 2023 | Tracy Curley Former Chief Executive Officer, Chief Financial Officer, Treasurer and Director | 350.0K | 87.5K | — | — | — | — | 437.5K | 0.00% | ↗ |
| 5 | 2023 | Benjamin Bielak Chief Information Officer | 326.0K | 65.2K | — | — | — | — | 391.2K | 0.00% | ↗ |
| 6 | 2023 | Benjamin Bielak Former Chief Information Officer | 326.0K | 65.2K | — | — | — | — | 391.2K | 0.00% | ↗ |
| 7 | 2022 | Tracy Curley Chief Executive Officer, Chief Financial Officer, Treasurer and Director | 313.4K | — | — | 77.0K | — | — | 390.4K | 19.72% | ↗ |
| 8 | 2022 | Tracy Curley Chief Executive Officer, Chief Financial Officer and Treasurer | 313.4K | — | — | 6.00 | — | — | 390.4K | 0.00% | ↗ |
| 9 | 2022 | Christopher Ianelli Former Chief Executive Officer, Former President and Director | 351.3K | 5.00 | — | — | — | 3.0K | 366.3K | 0.00% | ↗ |
| 10 | 2022 | Jill Mullan Former Chief Operating Officer, Former Secretary and Director | 328.8K | 5.00 | — | — | — | — | 348.8K | 0.00% | ↗ |
| 11 | 2022 | Benjamin Bielak Chief Information Officer | 301.9K | 6.0K | — | 23.1K | — | — | 331.0K | 6.98% | ↗ |
| 12 | 2021 | Christopher Ianelli Chief Executive, President and Director | 300.0K | 140.0K | 330.2K | — | — | — | 770.2K | 42.87% | ↗ |
| 13 | 2021 | Christopher Ianelli Former Chief Executive Officer, Former President and Director | 300.0K | 140.0K | 330.2K | — | — | — | 770.2K | 42.87% | ↗ |
| 14 | 2021 | Jill Mullan, Chief Operating Officer, Secretary and Director | 277.5K | 113.8K | 330.2K | — | — | — | 721.5K | 45.77% | ↗ |
| 15 | 2021 | Jill Mullan Former Chief Operating Officer, Former Secretary and Director | 277.5K | 113.8K | 330.2K | — | — | — | 721.5K | 45.77% | ↗ |
| 16 | 2021 | Benjamin Bielak Chief Information Officer | 250.0K | 84.0K | 300.2K | — | — | — | 634.2K | 47.33% | ↗ |
| 17 | 2021 | Tracy Curley Chief Executive Officer, Chief Financial Officer and Treasurer | 283.0K | 84.0K | 240.2K | — | — | — | 607.2K | 39.55% | ↗ |
| 18 | 2021 | Tracy Curley Chief Financial Officer and Treasurer | 283.0K | 84.0K | 240.2K | — | — | — | 607.2K | 39.55% | ↗ |
| 19 | 2020 | Christopher Ianelli Chief Executive, President and Director | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 20 | 2020 | Jill Mullan, Chief Operating Officer, Secretary and Director | 230.0K | — | — | — | — | — | 230.0K | 0.00% | ↗ |
| 21 | 2020 | Benjamin Bielak Chief Information Officer | 220.0K | — | — | — | — | — | 220.0K | 0.00% | ↗ |
| 22 | 2020 | Tracy Curley Chief Financial Officer and Treasurer | 105.6K | — | — | — | — | — | 105.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuying Liang | Chief Financial Officer | 314.5K | male |
| Katharyn Field | Chief Executive Officer, President, Secretary & Treasurer | 247.7K | female |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ISPC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
